Core Viewpoint - Aoxing Life Science Technology (06118.HK) anticipates a significant profit increase, projecting a net profit attributable to shareholders of at least RMB 30 million for the year ending December 31, 2025, compared to approximately RMB 16 million for the year ending December 31, 2024 [1] Group 1 - The notable profit growth is primarily attributed to the company's focus on strategic efficiency measures, particularly the optimization of administrative management and research and development (R&D) expenses, leading to a reduction in operating costs [1] - An increase in other income is expected, mainly driven by foreign exchange gains recorded for the year ending December 31, 2025 [1] - A decrease in financial costs is also contributing to the anticipated profit growth [1]
奥星生命科技(06118.HK)盈喜：预计2025年纯利不少于3000万元